578 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by OFI Invest Asset Management

OFI Invest Asset Management bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 578 shares of the medical research company’s stock, valued at approximately $110,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC increased its position in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. Cantillon Capital Management LLC grew its position in IQVIA by 12.3% in the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after acquiring an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. grew its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Impax Asset Management Group plc grew its position in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $188.72 on Tuesday. The business’s fifty day moving average price is $197.62 and its 200 day moving average price is $212.24. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $261.72. The stock has a market capitalization of $33.27 billion, a PE ratio of 25.16, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IQV. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Citigroup lowered their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Finally, UBS Group decreased their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.